Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency
Epistemonikos ID: 4c08269931099d1404991cc6fc879c81ac000834
First added on: May 05, 2024